Ankylosing spondylitis (AS) in inflammatory bowel disease (IBD) is associated with possession of HLA-B27 and DR1

Ankylosing spondylitis (AS) in inflammatory bowel disease (IBD) is associated with possession of HLA-B27 and DR1

Dades bibliogràfiques
Autors principals:	Orchard, T, Thiyagaraja, S, Welsh, K, Wordsworth, B, Jewell, D
Format:	Journal article
Publicat:	1997

Ítems similars

HLA genes are important phenotype determining genes in the peripheral arthropathies of inflammatory bowel disease (IBD).
per: Orchard, T, et al.
Publicat: (1998)

Genes of the HLA region are important in determining clinical phenotype in the peripheral arthropathies of inflammatory bowel disease (IBD).
per: Orchard, T, et al.
Publicat: (1998)

Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease.
per: Orchard, T, et al.
Publicat: (2000)

Ankylosing spondylitis: evidence for a non-HLA-B*27 protective effect - Reply
per: Brown, M, et al.
Publicat: (1998)

The effect of HLA-DR genes on susceptibility to and severity of ankylosing spondylitis.
per: Brown, M, et al.
Publicat: (1998)

HLA-B associations of HLA-B27 negative ankylosing spondylitis: comment on the article by Yamaguchi et al.
per: Brown, M, et al.
Publicat: (1996)

The role of HLA-B27 molecules in the pathogenesis of ankylosing spondylitis
per: A. Cauli, et al.
Publicat: (2002-09-01)

Association of Protective HLA-A With HLA-B∗27 Positive Ankylosing Spondylitis
per: Jessika Nordin, et al.
Publicat: (2021-07-01)

Ankylosing spondylitis in west Africans - evidence for a non-HLA-B*27 protective effect - reply
per: Brown, M, et al.
Publicat: (1997)

Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis.
per: Jaakkola, E, et al.
Publicat: (2006)

ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients.
per: Robinson, P, et al.
Publicat: (2015)

IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS), ADALIMUMAB IMPROVES INFLAMMATORY BOWEL DISEASE (IBD) AND PSORIASIS (Ps) AND PREVENTS ANTERIOR UVEITIS (AU) FLARES
per: Wordsworth, P, et al.
Publicat: (2009)

Ankylosing spondylitis in West Africans--evidence for a non-HLA-B27 protective effect.
per: Brown, M, et al.
Publicat: (1997)

Lipocalin 2 links inflammation and ankylosis in the clinical overlap of inflammatory bowel disease (IBD) and ankylosing spondylitis (AS)
per: Aifeng Lin, et al.
Publicat: (2020-03-01)

TARGETING MONOCYTE-EXPRESSED HLA-B27 HOMODIMERS IN ANKYLOSING SPONDYLITIS
per: Bowness, P, et al.
Publicat: (2010)

The role of ERAP1 and HLA-B27 in ankylosing spondylitis pathogenesis
per: Chen, L
Publicat: (2013)

TARGETING MONOCYTE-EXPRESSED HLA-B27 HOMODIMERS IN ANKYLOSING SPONDYLITIS
per: Bowness, P, et al.
Publicat: (2010)

Determination of HLA-B27 Subtypes in Iranian Patients with Ankylosing Spondylitis
per: Mohamad Hossein Nicknam, et al.
Publicat: (2008-03-01)

MHC class II and III genes are associated with ankylosing spondylitis independent of HLA-B27.
per: Sims, A, et al.
Publicat: (2004)

EXPRESSION OF HLA-B27 HEAVY CHAIN FORMS IN ANKYLOSING SPONDYLITIS AND HLA-B27 POSITIVE CELL LINES
per: Rysnik, O, et al.
Publicat: (2012)

Adalimumab (HUMIRA (R)) improves inflammatory bowel disease (IBD) and psoriasis (Ps) and prevents anterior uveitis (AU) flares in patients with Ankylosing spondylitis (AS)
per: Rudwaleit, M, et al.
Publicat: (2008)

Mapping of MHC class II and III genes associated with Ankylosing spondylitis independent of HLA-B27
per: Sims, A, et al.
Publicat: (2005)

Ankylosing spondylitis: evidence for a non-HLA-B*27 protective effect.
per: van der Linden, S, et al.
Publicat: (1998)

Clinical picture of ankylosing spondylitis in HLA-B27 positive and negative patients
per: Sh. F. Erdes, et al.
Publicat: (2023-10-01)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
per: Joachim Sieper, et al.
Publicat: (2023-08-01)

Predominant frequency of HLA‐B*27 in patients with ankylosing spondylitis in southeastern China
per: JiaoJiao Lu, et al.
Publicat: (2021-12-01)

Peripheral arthritis and inflammatory bowel disease.
per: Wordsworth, P, et al.
Publicat: (1998)

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.
per: Evans, D, et al.
Publicat: (2011)

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility
per: Evans, D, et al.
Publicat: (2011)

Non-B27 MHC associations of ankylosing spondylitis.
per: Sims, A, et al.
Publicat: (2007)

The role of NK family receptor interactions with HLA-B27 in Ankylosing Spondylitis pathogenesis
per: Giles, J
Publicat: (2011)

Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database
per: Marta Arévalo, et al.
Publicat: (2018-10-01)

Intravitreal Triamcinolone Acetonide for Macular Edema in HLA-B27 Negative Ankylosing Spondylitis
per: M.M. Moschos, et al.
Publicat: (2010-12-01)

Association of ORAI1 haplotypes with the risk of HLA-B27 positive ankylosing spondylitis.
per: James Cheng-Chung Wei, et al.
Publicat: (2011-01-01)

Disease severity in Ankylosing Spondylitis: The influence of associated inflammatory bowel disease and psoriasis
per: Bradbury, L, et al.
Publicat: (2008)

MHC associations of ankylosing spondylitis in East Asians are complex and involve non-HLA-B27 HLA contributions
per: Geng Wang, et al.
Publicat: (2020-04-01)

MAPPING THE NON-B27 MHC ASSOCIATIONS OF ANKYLOSING SPONDYLITIS (AS)
per: Sims, A, et al.
Publicat: (2004)

Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients
per: Matthew L. Stoll, et al.
Publicat: (2022-04-01)

Correction to: Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database
per: Marta Arévalo, et al.
Publicat: (2020-06-01)

Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment.
per: Brown, M, et al.
Publicat: (1997)